Localization and functional characterization of glycosaminoglycan domains in the normal human kidney as revealed by phage display-derived single chain antibodies

Journal of the American Society of Nephrology

Volumn 16, Issue 5, 2005, Pages 1279-1288

  Lensen, Joost F M ^a   Rops, Angelique L W M M ^a   Wijnhoven, Tessa J M ^a   Hafmans, Theo ^a   Feitz, Wouter F J ^a   Oosterwijk, Egbert ^a   Banas, Bernhard ^b   Bindels, René J M ^a   Van Den Heuvel, Lambert P W J ^a   Van Der Vlag, Johan ^a   Berden, Jo H M ^a   Van Kuppevelt, Toin H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDROITIN SULFATE; CORE PROTEIN; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HS4C3 ANTIBODY; KIDNEY ANTIBODY; PROTEOGLYCAN; RB4EA12 ANTIBODY; UNCLASSIFIED DRUG; ANTIBODY; PEPTIDE LIBRARY;

ADULT; ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOELECTRON MICROSCOPY; MALE; MESANGIUM CELL; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DOMAIN; ANTIBODY SPECIFICITY; CHEMISTRY; FLUORESCENCE MICROSCOPY; GENETICS; IMMUNOLOGY; MESANGIUM; METABOLISM; MIDDLE AGED; PROTEIN TERTIARY STRUCTURE; ULTRASTRUCTURE;

ADULT; ANTIBODIES; ANTIBODY SPECIFICITY; CHONDROITIN SULFATES; FEMALE; FIBROBLAST GROWTH FACTOR 2; GLOMERULAR MESANGIUM; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; MICROSCOPY, IMMUNOELECTRON; MIDDLE AGED; PEPTIDE LIBRARY; PROTEIN STRUCTURE, TERTIARY;

EID: 23944441820     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004050413     Document Type: Article

References (50)

1. Esko JD, Lindahl U: Molecular diversity of heparan sulfate. J Clin Invest 108: 169-173, 2001
2. Conrad HE: Heparin-Binding Proteins, New York, Academic Press, 1998
3. Tumova S, Woods A, Couchman JR: Heparan sulfate proteoglycans on the cell surface: Versatile coordinators of cellular functions. Int J Biochem Cell Biol 32: 269-288, 2000
4. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68: 729-777, 1999
5. Forsberg E, Kjellen L: Heparan sulfate: Lessons from knockout mice. J Clin Invest 108: 175-180, 2001
6. Li JP, Gong F, Hagner-McWhirter A, Forsberg E, Abrink M, Kisilevsky R, Zhang X, Lindahl U: Targeted disruption of a murine glucuronyl C5-epimerase gene results in heparan sulfate lacking L-iduronic acid and in neonatal lethality. J Biol Chem 278: 28363-28366, 2003
7. Filmus J, Selleck SB: Glypicans: Proteoglycans with a surprise. J Clin Invest 108: 497-501, 2001
8. van den Born J, van Kraats AA, Bakker MA, Assmann KJ, van den Heuvel LP, Veerkamp JH, Berden JH: Selective proteinuria in diabetic nephropathy in the rat is associated with a relative decrease in glomerular basement membrane heparan sulphate. Diabetologia 38: 161-172, 1995
9. Raats CJ, van den Born J, Berden JH: Glomerular heparan sulfate alterations: Mechanisms and relevance for proteinuria. Kidney Int 57: 385-400, 2000
10. Stevens FJ, Kisilevsky R: Immunoglobulin light chains, glycosaminoglycans, and amyloid. Cell Mol Life Sci 57: 441-449, 2000
11. Conde-Knape K: Heparan sulfate proteoglycans in experimental models of diabetes: A role for perlecan in diabetes complications. Diabetes Metab Res Rev 17: 412-421, 2001
12. van den Heuvel LP, Westenend PJ, van den Born J, Assmann KJ, Knoers N, Monnens LA: Aberrant proteoglycan composition of the glomerular basement membrane in a patient with Denys-Drash syndrome. Nephrol Dial Transplant 10: 2205-2211, 1995
13. Rops AL, van der Vlag J, Lensen JF, Wijnhoven TJ, van den Heuvel LP, van Kuppevelt TH, Berden JH: Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int 65: 768-785, 2004
14. Maccarana M, Sakura Y, Tawada A, Yoshida K, Lindahl U: Domain structure of heparan sulfates from bovine organs. J Biol Chem 271: 17804-17810, 1996
15. Saad OM, Leary JA: Compositional analysis and quantification of heparin and heparan sulfate by electrospray ionization ion trap mass spectrometry. Anal Chem 75: 2985-2995, 2003
16. Tekotte H, Engel M, Margolis RU, Margolis RK: Disaccharide composition of heparan sulfates: Brain, nervous tissue storage organelles, kidney, and lung. J Neurochem 62: 1126-1130, 1994
17. Westling C, Lindahl U: Location of N-unsubstituted glucosamine residues in heparan sulfate. J Biol Chem 277: 49247-49255, 2002
18. van den Born J, van Kraats AA, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH: Monoclonal antibodies against the protein core and glycosaminoglycan side chain of glomerular basement membrane heparan sulfate proteoglycan: Characterization and immunohistological application in human tissues. J Histochem Cytochem 42: 89-102, 1994
19. van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH: Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 273: 12960-12966, 1998
20. van de Westerlo EM, Smetsers TF, Dennissen MA, Linhardt RJ, Veerkamp JH, van Muijen GN, van Kuppevelt TH: Human single chain antibodies against heparin: Selection, characterization, and effect on coagulation. Blood 99: 2427-2433, 2002
21. Dennissen MA, Jenniskens GJ, Pieffers M, Versteeg EM, Petitou M, Veerkamp JH, van Kuppevelt TH: Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies. J Biol Chem 277: 10982-10986, 2002
22. Muller M, Marti T, Kriz S: Improved structural preservation by freeze-substitution [Abstract]. 7th European Congress on Electron Microscopy 2: 720-721, 1980
23. Pieper JS, Hafmans T, van Wachem PB, van Luyn MJ, Brouwer LA, Veerkamp JH, van Kuppevelt TH: Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. J Biomed Mater Res 62: 185-194, 2002
24. Banas B, Luckow B, Moller M, Klier C, Nelson PJ, Schadde E, Brigl M, Halevy D, Holthofer H, Reinhart B, Schlondorff D: Chemokine and chemokine receptor expression in a novel human mesangial cell line. J Am Soc Nephrol 10: 2314-2322, 1999
25. Floege J, Hudkins KL, Eitner F, Cui Y, Morrison RS, Schelling MA, Alpers CE: Localization of fibroblast growth factor-2 (basic FGF) and FGF receptor-1 in adult human kidney. Kidney Int 56: 883-897, 1999
26. Esko JD, Selleck SB: Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 71: 435-471, 2002
27. Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE: Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269: 18881-18890, 1994
28. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59: 1324-1332, 2001
29. Ye S, Luo Y, Lu W, Jones RB, Linhardt RJ, Capila I, Toida T, Kan M, Pelletier H, McKeehan WL: Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs. Biochemistry 40: 14429-14439, 2001
30. Ostrovsky O, Berman B, Gallagher J, Mulloy B, Fernig DG, Delehedde M, Ron D: Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes. J Biol Chem 277: 2444-2453, 2002
31. Clayton A, Thomas J, Thomas GJ, Davies M, Steadman R: Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2. Kidney Int 59: 2084-2094, 2001
32. Maccarana M, Casu B, Lindahl U: Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem 268: 23898-23905, 1993
33. Floege J, Burg M, Hugo C, Gordon KL, Van Goor H, Reidy M, Couser WG, Koch KM, Johnson RJ: Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangioproliferative glomerulonephritis. J Am Soc Nephrol 9: 792-801, 1998
34. Strutz F, Zeisberg M, Hemmerlein B, Sattler B, Hummel K, Becker V, Muller GA: Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int 57: 1521-1538, 2000
35. Shima H, Tazawa H, Puri P: Increased expression of fibroblast growth factors in segmental renal dysplasia. Pediatr Surg Int 16: 306-309, 2000
36. Ray PE, Liu XH, Xu L, Rakusan T: Basic fibroblast growth factor in HIV-associated hemolytic uremic syndrome. Pediatr Nephrol 13: 586-593, 1999
37. Morita H, Shinzato T, David G, Mizutani A, Habuchi H, Fujita Y, Ito M, Asai J, Maeda K, Kimata K: Basic fibroblast growth factor-binding domain of heparan sulfate in the human glomerulosclerosis and renal tubulointerstitial fibrosis. Lab Invest 71: 528-535, 1994
38. Petitou M, Herault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, Herbert JM: Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398: 417-422, 1999
39. Poplawska A, Szelachowska M, Topolska J, Wysocka-Solowie B, Kinalska I: Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract 38: 109-114, 1997
40. Solini A, Vergnani L, Ricci F, Crepaldi G: Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 20: 819-823, 1997
41. Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlova M, Olsovsky J, Manitius J, Fedele D, Czekalski S, Perusicova J, Skrha J, Taton J, Grzeszczak W, Crepaldi G: Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial. J Am Soc Nephrol 13: 1615-1625, 2002
42. van der Pijl JW, Lemkes HH, Frolich M, van der Woude FJ, van der Meer FJ, van Es LA: Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2. J Am Soc Nephrol 10: 1331-1336, 1999
43. Yokoyama H, Sato K, Okudaira M, Morita C, Takahashi C, Suzuki D, Sakai H, Iwamoto Y: Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy. Kidney Int 56: 650-658, 1999
44. Feyzi E, Saldeen T, Larsson E, Lindahl U, Salmivirta M: Age-dependent modulation of heparan sulfate structure and function. J Biol Chem 273: 13395-13398, 1998
45. Smetsers TFCM, van de Westerlo EMA, ten Dam GB, Overes IM, Schalkwijk J, van Muijen GNP, van Kuppevelt TH: Human single-chain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis. J Investig Dermatol 122: 707-716, 2004
46. Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA: Aquaporins in the kidney: From molecules to medicine. Physiol Rev 82: 205-244, 2002
47. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D: Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 10: 647-663, 1999
48. van den Born J, van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH: Production and characterization of a monoclonal antibody against human glomerular heparan sulfate. Lab Invest 65: 287-297, 1991
49. Kriz W, Kaissling B: Structural Organization of the Mammalian Kidney. In: The Kidney: Physiology and Pathophysiology, edited by Seldin DW, Giebisch G, New York, Raven Press, 1985, pp 265-306
50. Reilly RF, Ellison DH: Mammalian distal tubule: Physiology, pathophysiology, and molecular anatomy. Physiol Rev 80: 277-313, 2000